Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
The Journal of Clinical Investigation|December 23, 2025
Mismatch repair deficiency drives malignant progression and alters the tumor immune microenvironment in glioblastoma modelsMontserrat Puigdelloses Vallcorba, Nishant Soni, Seung-Won Choi, et al.Nature Genetics|January 5, 2021
The association between tumor mutational burden and prognosis is dependent on treatment contextCristina Valero, Mark Lee, Douglas Hoen, et al.Nature Cancer|April 9, 2021
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapyRobert M Samstein, Chirag Krishna, Xiaoxiao Ma, et al.Immunity|June 8, 2020
Immunology of COVID-19: Current State of the ScienceNicolas Vabret, Graham J Britton, Conor Gruber, et al.Nature Medicine|April 24, 2019
Immunogenic neoantigens derived from gene fusions stimulate T cell responsesWei Yang, Ken-Wing Lee, Raghvendra M Srivastava, et al.Nature Genetics|July 11, 2022
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunityXiaoxiao Ma, Nadeem Riaz, Robert M Samstein, et al.Cancer Immunology Research|September 21, 2021
Supporting the Next Generation of Scientists to Lead Cancer Immunology ResearchElise Alspach, Ryan D Chow, Shadmehr Demehri, et al.Nature Biotechnology|November 2, 2021
Improved prediction of immune checkpoint blockade efficacy across multiple cancer typesDiego Chowell, Seong-Keun Yoo, Cristina Valero, et al.Journal of the National Cancer Institute|July 30, 2020
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic EfficacyKenneth L Pitter, Dana L Casey, Yue C Lu, et al.Nature Medicine|October 2, 2023
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trialMatthew D Galsky, Siamak Daneshmand, Sudeh Izadmehr, et al.Pageof 5